EVANSTON, Ill., Sept. 13 /PRNewswire-FirstCall/ --
Northfield Laboratories Inc. (Nasdaq: NFLD), announced that the preliminary
results from the annual meeting of the Company's shareholders held earlier
today indicate that the Company's director nominees defeated the slate of
board nominees nominated by a dissident shareholder. Once the independent
inspectors of election for the meeting have completed their final tabulation,
they will provide a written report of the results and Northfield will issue a
press release announcing the final results. Dr. Steven A. Gould, Northfield's
Chairman and Chief Executive Officer, said, "I am pleased the preliminary
results indicate that all of Northfield's director nominees have been elected.
I look forward to working with our directors as we pursue our goal of
increasing shareholder value during this next year."
Dr. Gould made further comments regarding today's annual meeting. "I was
gratified at the large number of shareholders attending our annual meeting
today. On the heels of the long proxy contest, I appreciate the input of our
shareholders. I believe that my presentation was helpful in providing an
updated description of our current regulatory status. The meeting represented
an opportunity for Northfield to describe in detail its progress with the FDA.
I received many favorable comments during the coffee session following the
presentation. I welcomed the opportunity to inform our shareholders about the
potential benefit of additional clinical trials in broadening the indication
for use, fast track designation and other regulatory review matters."
Dr. Gould also provided his view of the opportunities for raising
additional capital and securing a pharmaceutical partner. He spent a
considerable amount of time describing his desire to enhance investor
relations in a number of ways, including quarterly conference calls, frequent
news updates, the hiring of an internal Investor Relations Director, outreach
to potential new investors, and his goal of broadening media awareness of
Northfield and PolyHeme(TM).
Statements in this release that are not strictly historical are "forward-
looking" statements that are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements involve known and unknown risks, which may cause the company's
actual results in the future to differ materially from expected results. These
risks include, among others: competition from other blood substitute products;
the company's ability to obtain regulatory approval to market PolyHeme
commercially; the company's and/or its representative's ability to
successfully market and sell PolyHeme; the company's ability to manufacture
PolyHeme in sufficient quantities; the company's ability to obtain an adequate
supply of raw materials; the company's ability to maintain intellectual
property protection for its proprietary product and to defend its existing
intellectual property rights from challenges by third parties; the
availability of capital to finance planned growth; and the extent to which the
hospitals and physicians using PolyHeme are able to obtain third-party
reimbursement, as described in the company's filings with the Securities and
Exchange Commission.
Visit the Northfield website at: http://www.northfieldlabs.com .
SOURCE Northfield Laboratories Inc.
 back to top
Related links:
http://www.northfieldlabs.com
CONTACT:
Steven A. Gould, M.D., Chief Executive
Officer of Northfield Laboratories, +1-847-864-3500, or
Investors, Lisa Fortuna, +1-312-640-6779, or Media, Cindy Martin,
+1-312-640-6741, both of FRB Weber Shandwick
|
